The disconnect between Rocket Lab’s operational trajectory and its stock price has rarely been wider. While the company has locked in a record $2.2 billion order book, secured a $266 million Space Force contract, and just announced an $8 billion acquisition of Iridium Communications, its shares have been shredded in a sector-wide rout. On Friday, the stock closed at €56.40, down 8.29% on the day and nearly 25% over the past month. That leaves the equity 57.85% below its 52-week high of €133.80 set on May 27 — a collapse that has little to do with the company’s own execution.
The sell-off has been exacerbated by two factors that, on closer inspection, look more like noise than signal. First, the stock breached a psychologically important level tied to the Iridium deal’s structure. Second, CEO Peter Beck sold shares in early July. But those sales were executed through a Rule 10b5-1 trading plan established on March 27, 2026 — a routine diversification mechanism, not a vote of no confidence. The market’s reaction, in other words, appears technically driven rather than fundamentally warranted.
A Vertically Integrated Bet That the Market Hasn’t Priced
Rocket Lab’s strategic narrative has shifted dramatically. No longer just a small-satellite launch provider, the company is positioning itself as a vertically integrated space powerhouse through the $8 billion Iridium acquisition — a mix of cash and stock that promises recurring satellite-service revenue to replace the cyclicality of the launch business. The logic is sound, but the market has yet to fully digest it.
The operational evidence is mounting. Beyond the $2.2 billion backlog, Rocket Lab completed the Victus Haze rapid-response mission for the U.S. Space Force in June and secured a major GEO satellite contract in May. It also holds a role in the National Security Space Launch program, a contract vehicle worth up to $17 billion. The Neutron medium-lift rocket, whose debut is targeted for the fourth quarter of 2026, remains the single most important catalyst for the long-term thesis.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Yet the stock continues to bleed. The annualized 30-day volatility stands at 88.21%, making violent swings in both directions the norm. The 14-day relative strength index has fallen to 30.8, flirting with oversold territory, while the share price sits 16.27% below its 200-day moving average of €67.36 — a warning for long-term support, but also a sign of technical exhaustion rather than a fundamental re-rating.
The Fed, the Neutron, and the August 10 Deadline
Short-term sentiment will be shaped by the Federal Reserve’s meeting on July 28-29. A dovish outcome could provide the relief that growth stocks like Rocket Lab desperately need. But the real test comes on August 10, when the company reports second-quarter results after the U.S. market close. Positive operational updates could serve as the trigger for a trend reversal.
Analysts see a consensus price target of €100.50, implying 78.2% upside from Friday’s close. That gap between execution and valuation is striking. The company has already delivered on its promises — the Iridium deal, the Space Force contracts, the record backlog. The question now is whether the market is willing to look past the sector-wide turbulence and refocus on that substance before the next hard numbers land.
For investors who can stomach the volatility, the stock still shows a 37.56% gain over the past twelve months. The current weakness looks less like a structural breakdown and more like a correction within an intact uptrend — provided Neutron stays on schedule and the Iridium integration proceeds without a hitch.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from July 26 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 26.
Rocket Lab: Buy or sell? Read more here...
